PR Newswire Clinical TrialsOriginal article
Immorta Bio Pioneers AI-Designed Senolytic Immunotherapy Targeting Diseases of Aging
Trial StartPositive
AI Analysis
Summary
Immorta Bio announced an AI-designed nine-amino-acid peptide senolytic immunotherapy targeting diseases of aging, with clinical entry planned for 2026. The therapy is designed to restore the immune system's ability to eliminate senescent cells.
Outcome Details
Clinical entry planned for 2026
Importance:5/10
Sentiment:
0.70
senolyticimmunotherapyagingAI-designedsenescent cells
Read the original article
Published by PR Newswire Clinical Trials on October 12, 2026 1:22 PM